The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp262
APPLICATIONS OF AI IN GI/HEPATOLOGY CLINICAL PRACTICE: PRESENT AND FUTURE
Date
May 6, 2023
Explore related products in the following collection:
This session will provide an overview of present and future applications of artificial intelligence in the clinical practice of gastroenterology and hepatology, and highlight ethical, legal/regulatory, and equity considerations for use of AI in patient care. Practical strategies will be provided for mitigation of these concerns. The session includes a diverse roster of speakers representing perspectives gleaned by differences in age, gender, race and experience.
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…